Xaliproden hydrochloride

Pricing Availability   Qty
Cat.No. 2491 - Xaliproden hydrochloride | C24H22F3N.HCl | CAS No. 90494-79-4
Description: High affinity 5-HT1A agonist; orally active
Alternative Names: SR 57746A
Chemical Name: 1,2,3,6-Tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-pyridine hydrochloride
Purity: ≥99% (HPLC)
Citations (1)
Literature (5)

Biological Activity for Xaliproden hydrochloride

Xaliproden hydrochloride is an orally active, full agonist at 5-HT1A receptors. Binds rat 5-HT1A with high affinity (Ki = 2.0 nM) and is > 300-fold selective over other 5-HT receptor subtypes (IC50 > 650 nM). Increases motoneuron survival and promotes effects of NGF on neurite outgrowth in vitro. Displays neurotrophic activity in several neurodegenerative models in vivo..

Technical Data for Xaliproden hydrochloride

M. Wt 417.9
Formula C24H22F3N.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 90494-79-4
PubChem ID 128918
Smiles Cl.FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C3C=CC=CC3=C2)CC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Xaliproden hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 41.79 100
ethanol 8.36 20

Preparing Stock Solutions for Xaliproden hydrochloride

The following data is based on the product molecular weight 417.9. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.39 mL 11.96 mL 23.93 mL
5 mM 0.48 mL 2.39 mL 4.79 mL
10 mM 0.24 mL 1.2 mL 2.39 mL
50 mM 0.05 mL 0.24 mL 0.48 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for Xaliproden hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Xaliproden hydrochloride

References are publications that support the biological activity of the product.

Fournier et al (1993) Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55 629 PMID: 8413926

Duong et al (1999) Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons. Br.J.Pharmacol. 128 1385 PMID: 10602316

Bachy et al (1993) Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist. Fund.Clin.Pharmacol. 7 487

If you know of a relevant reference for Xaliproden hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Agonists

Keywords: Xaliproden hydrochloride, Xaliproden hydrochloride supplier, Orally, active, high, affinity, 5-HT1A, agonists, Serotonin, Receptors, SR57746A, SR, 57746A, 2491, Tocris Bioscience

1 Citation for Xaliproden hydrochloride

Citations are publications that use Tocris products. Selected citations for Xaliproden hydrochloride include:

Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacol 175 PMID: 32088264

Do you know of a great paper that uses Xaliproden hydrochloride from Tocris? Please let us know.

Reviews for Xaliproden hydrochloride

There are currently no reviews for this product. Be the first to review Xaliproden hydrochloride and earn rewards!

Have you used Xaliproden hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.